Back to Search Start Over

Oral acetazolamide for intraocular pressure lowering: balancing efficacy and safety in ophthalmic practice.

Authors :
Gulati S
Aref AA
Source :
Expert review of clinical pharmacology [Expert Rev Clin Pharmacol] 2021 Aug; Vol. 14 (8), pp. 955-961. Date of Electronic Publication: 2021 May 25.
Publication Year :
2021

Abstract

Introduction : Systemic acetazolamide is an efficacious adjunct to topical therapy to lower intraocular pressure (IOP) in glaucomatous eyes. This article aims to provide a comprehensive review for how best to use the agent in ophthalmic practice. Areas covered : This article will review the history, mechanism of action, methods of observing efficacy, indications for IOP lowering, side effects, allergy information including discussion of limited cross-reactivity between antimicrobial and non-antimicrobial sulfonamides, formulations, dosing and monitoring of acetazolamide. To select articles for this review, an electronic search was conducted using the PubMed database and cross-referencing was conducted for relevant literature. Expert opinion : The benefits of oral carbonic anhydrase inhibitor therapy can outweigh the risks in many circumstances. It is important that eye care practitioners work together with a patient's primary care practitioner to monitor for and mitigate risks. Greater education is needed with regard to the allergy profile of these powerful agents. Though not often a first-line option, oral carbonic anhydrase inhibitors remain pivotal and play in important role in delivery of eye care.

Details

Language :
English
ISSN :
1751-2441
Volume :
14
Issue :
8
Database :
MEDLINE
Journal :
Expert review of clinical pharmacology
Publication Type :
Academic Journal
Accession number :
34003717
Full Text :
https://doi.org/10.1080/17512433.2021.1931123